Valuation Insights | Analysts set price targets ranging from $10 to $16, reflecting varied perspectives on CureVac's potential amid its pivotal year of clinical advancements and IP litigation outcomes |
Catalysts on Horizon | Anticipate key milestones in 2025-2026, including GBM vaccine results and ExPEC IND filing, potentially reshaping CureVac's market position and investor sentiment |
Financial Fortitude | With a robust cash position of €438 million funding operations into 2028, CureVac demonstrates financial stability amidst market challenges and ongoing clinical developments |
mRNA Pioneer's Edge | CureVac's innovative mRNA platform underpins a diverse pipeline, including promising vaccine candidates for glioblastoma and ExPEC, positioning it at the forefront of genetic medicine |
Metrics to compare | CVAC | Peers Peers - average of corresponding metrics from companies closely matching CVAC: | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipCVACPeersSector |
|---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | −0.2x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price / Book | 0.0x | 0.0x | 2.6x | |
Price / LTM Sales | 0.0x | 0.0x | 2.7x | |
Upside (Analyst Target) | - | 0.0% | 72.2% | |
Fair Value Upside | Unlock | 0.0% | 12.4% | Unlock |